Jensen Investment Management Inc. Reduces Position in Zoetis Inc. (NYSE:ZTS)

Jensen Investment Management Inc. lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,123,398 shares of the company’s stock after selling 26,972 shares during the quarter. Zoetis comprises 3.1% of Jensen Investment Management Inc.’s investment portfolio, making the stock its 13th biggest holding. Jensen Investment Management Inc. owned about 0.47% of Zoetis worth $345,965,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC lifted its position in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. lifted its position in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares during the period. Darwin Wealth Management LLC acquired a new stake in Zoetis during the 3rd quarter worth approximately $31,000. Dunhill Financial LLC lifted its position in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Finally, Asset Planning Inc acquired a new stake in Zoetis during the 4th quarter worth approximately $58,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $161.33 on Monday. The stock has a fifty day moving average price of $166.82 and a 200 day moving average price of $176.10. The stock has a market cap of $72.24 billion, a PE ratio of 29.49, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.24%. Zoetis’s dividend payout ratio is presently 36.56%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ZTS. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $215.90.

Insider Buying and Selling

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.